Results 211 to 220 of about 1,192,795 (361)
Significance of Participants’ Expectations in Managing the Placebo Effect in Antidepressant Research
Marko Curkovic +3 more
doaj +1 more source
Efficacy and Safety of <i>Ecklonia cava</i> Kjellman Extract Complex in Respiratory Health: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. [PDF]
Woo SC +8 more
europepmc +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial [PDF]
Gail M. Gauvreau +27 more
openalex +1 more source
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro +17 more
wiley +1 more source
The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire. [PDF]
Jeryous Fares B +9 more
europepmc +1 more source
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli +4 more
wiley +1 more source

